{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:58Z","timestamp":1786991878444,"version":"build-2736575974"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jconrel.2023.10.002","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T07:09:55Z","timestamp":1696835395000},"page":"507-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication"],"prefix":"10.1016","volume":"363","author":[{"given":"Ali","family":"Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Bremmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive A.","family":"Prestidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","article-title":"The physiology of the lymphatic system","volume":"50","author":"Swartz","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0010","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/cells11060979","article-title":"Pathogenic exploitation of lymphatic vessels","volume":"11","author":"Magold","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-immunol-041015-055354","article-title":"The lymphatic system: integral roles in immunity","volume":"35","author":"Randolph","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/cells11010033","article-title":"Bacterial lymphatic metastasis in infection and immunity","volume":"11","author":"Siggins","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI83379","article-title":"Lymphatic endothelial cells are a replicative niche for mycobacterium tuberculosis","volume":"126","author":"Lerner","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1099\/vir.0.025395-0","article-title":"Human cytomegalovirus productively infects lymphatic endothelial cells and induces a secretome that promotes angiogenesis and lymphangiogenesis through interleukin-6 and granulocyte\u2013macrophage colony-stimulating factor","volume":"92","author":"Fiorentini","year":"2011","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0035","series-title":"Developmental Aspects of the Lymphatic Vascular System","first-page":"23","article-title":"Mechanosensing in developing lymphatic vessels","author":"Planas-Paz","year":"2014"},{"issue":"424","key":"10.1016\/j.jconrel.2023.10.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7964","article-title":"Methicillin-resistant Staphylococcus aureus causes sustained collecting lymphatic vessel dysfunction","volume":"10","author":"Jones","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.002_bb0045","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fimmu.2017.00324","article-title":"Oxygen levels and immunological studies","volume":"8","author":"Zenewicz","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.addr.2019.08.009","article-title":"Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors","volume":"144","author":"Cote","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0060","doi-asserted-by":"crossref","first-page":"101899","DOI":"10.1016\/j.jddst.2020.101899","article-title":"Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: an insight into the in-vitro, ex-vivo, in-situ and in-vivo study models","volume":"59","author":"Chaturvedi","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"22","key":"10.1016\/j.jconrel.2023.10.002_bb0065","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1177\/15353702211010762","article-title":"Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes","volume":"246","author":"Trac","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0070","doi-asserted-by":"crossref","first-page":"113914","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4049\/jimmunol.1701254","article-title":"Salmonella enterica serovar typhimurium travels to mesenteric lymph nodes both with host cells and autonomously","volume":"202","author":"Bravo-Blas","year":"2019","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004587","article-title":"Dissemination of a highly virulent pathogen: tracking the early events that define infection","volume":"11","author":"Gonzalez","year":"2015","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18454-0","article-title":"Extracellular bacterial lymphatic metastasis drives streptococcus pyogenes systemic infection","volume":"11","author":"Siggins","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007337","article-title":"Lymph nodes are sites of prolonged bacterial persistence during mycobacterium tuberculosis infection in macaques","volume":"14","author":"Ganchua","year":"2018","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0095","first-page":"303","article-title":"Lymphatic circulation disseminates Bartonella infection into bloodstream","volume":"215","author":"Hong","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21724-0","article-title":"Persistence of viral RNA in lymph nodes in ART-suppressed SIV\/SHIV-infected Rhesus macaques","volume":"12","author":"Cadena","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.002_bb0105","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1128\/JVI.02947-15","article-title":"Lymphatic dissemination of simian immunodeficiency virus after penile inoculation","volume":"90","author":"Ma","year":"2016","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.002_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004440","article-title":"Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract","volume":"10","author":"Stieh","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0115","first-page":"27","article-title":"Travelling with dengue: from the skin to the nodes","author":"Marcial-Ju\u00e1rez","year":"2017","journal-title":"Dengue-Immunopathol. Control Strateg."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10675-2","article-title":"Inherent biomechanical traits enable infective filariae to disseminate through collecting lymphatic vessels","volume":"10","author":"Kilarski","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41385-021-00389-4","article-title":"Human gut-associated lymphoid tissues (GALT); diversity, structure, and function","volume":"14","author":"M\u00f6rbe","year":"2021","journal-title":"Mucosal Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-X","article-title":"Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules","volume":"34","author":"Charman","year":"1986","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.002_bb0135","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","article-title":"An update on oral drug delivery via intestinal lymphatic transport","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0140","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1039\/C7NR06052A","article-title":"Self-discriminating fluorescent hybrid nanocrystals: efficient and accurate tracking of translocation via oral delivery","volume":"10","author":"Shen","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jconrel.2017.11.046","article-title":"Epithelia transmembrane transport of orally administered ultrafine drug particles evidenced by environment sensitive fluorophores in cellular and animal studies","volume":"270","author":"Xie","year":"2018","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.002_bb0155","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/acs.molpharmaceut.6b00226","article-title":"Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats","volume":"13","author":"Shi","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2016.07.051","article-title":"Role of nanoparticle size, shape and surface chemistry in oral drug delivery","volume":"238","author":"Banerjee","year":"2016","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2005.04.006","article-title":"Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer\u2019s patches in mice","volume":"61","author":"Shakweh","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.002_bb0170","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.drudis.2014.03.001","article-title":"Ligand-mediated active targeting for enhanced oral absorption","volume":"19","author":"Zhang","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-018-1262-2","article-title":"Active targeting of drugs and bioactive molecules via oral administration by ligand-conjugated lipidic nanocarriers: recent advances","volume":"20","author":"Shreya","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0180","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.28166","article-title":"Recent advances in oral vaccine development: yeast-derived \u03b2-glucan particles","volume":"10","author":"De Smet","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0264-410X(01)00258-4","article-title":"Targeting polymerised liposome vaccine carriers to intestinal M cells","volume":"20","author":"Clark","year":"2001","journal-title":"Vaccine"},{"issue":"69","key":"10.1016\/j.jconrel.2023.10.002_bb0190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1098\/rsif.2011.0751","article-title":"Modelling the lymphatic system: challenges and opportunities","volume":"9","author":"Margaris","year":"2012","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0195","series-title":"The Sentinel Lymph Node Concept","author":"Schauer","year":"2005"},{"issue":"16","key":"10.1016\/j.jconrel.2023.10.002_bb0200","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.18632\/aging.102213","article-title":"Pathophysiology of aged lymphatic vessels","volume":"11","author":"Shang","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cell.2020.06.039","article-title":"The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease","volume":"182","author":"Oliver","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.002_bb0215","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/jm00186a001","article-title":"Prodrugs and site-specific drug delivery","volume":"23","author":"Stella","year":"1980","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2021.12.003","article-title":"Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport","volume":"341","author":"Elz","year":"2021","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","article-title":"Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update","volume":"60","author":"Trevaskis","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"D1","key":"10.1016\/j.jconrel.2023.10.002_bb0230","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0235","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijpharm.2007.05.064","article-title":"Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route","volume":"344","author":"Lalanne","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/COH.0000000000000686","article-title":"HIV persistence in lymph nodes","volume":"16","author":"Banga","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2011.05.005","article-title":"A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary","volume":"414","author":"Skanji","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0250","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0255","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jconrel.2020.10.036","article-title":"Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach","volume":"329","author":"Qin","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0260","first-page":"19","article-title":"Catalytic enzyme activity concentration in thoracic duct, liver, and intestinal lymph of the dog, the rabbit, the rat and the mouse. Approach to a quantitative diagnostic enzymology, II. Communication","volume":"24","author":"Lindena","year":"1986","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0265","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2018.07.022","article-title":"Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system","volume":"286","author":"Lee","year":"2018","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0270","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejpb.2017.12.012","article-title":"Supersaturated silica-lipid hybrids (super-SLH): an improved solid-state lipid-based oral drug delivery system with enhanced drug loading","volume":"125","author":"Schultz","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0280","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/17425247.2019.1605353","article-title":"An update on polymer-lipid hybrid systems for improving oral drug delivery","volume":"16","author":"Maghrebi","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0285","doi-asserted-by":"crossref","first-page":"102934","DOI":"10.1016\/j.jddst.2021.102934","article-title":"Lymphatic transport system to circumvent hepatic metabolism for oral delivery of lipid-based nanocarriers","volume":"66","author":"Rajput","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-409X(00)00121-6","article-title":"Lymphatic targeting with nanoparticulate system","volume":"47","author":"Nishioka","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0928-0987(02)00051-9","article-title":"Lipid-based formulations for intestinal lymphatic delivery","volume":"15","author":"O\u2019Driscoll","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.colsurfb.2010.04.005","article-title":"Solvent injection-lyophilization of tert-butyl alcohol\/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles","volume":"79","author":"Wang","year":"2010","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.002_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2010.10.002","article-title":"Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting","volume":"42","author":"Alex","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0315","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijpharm.2015.09.014","article-title":"Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach","volume":"495","author":"Makwana","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.002_bb0320","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/17425247.2014.915310","article-title":"Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation","volume":"11","author":"Siram","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0325","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2018.11.006","article-title":"Solidification to improve the biopharmaceutical performance of SEDDS: opportunities and challenges","volume":"142","author":"Joyce","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0330","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.colsurfb.2016.02.012","article-title":"Systematic development of solid self-nanoemulsifying oily formulations (S-SNEOFs) for enhancing the oral bioavailability and intestinal lymphatic uptake of lopinavir","volume":"141","author":"Garg","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0335","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejps.2004.12.006","article-title":"Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs","volume":"24","author":"Dahan","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0340","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejps.2011.04.011","volume":"43","author":"Sun","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0345","series-title":"Infectious Diseases","article-title":"Antiparasitic agents","author":"Kuhlmann","year":"2017"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0350","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0355","first-page":"1057","article-title":"Self-nanoemulsifying drug delivery system of mebendazole for treatment of lymphatic filariasis","volume":"80","author":"Rao","year":"2018","journal-title":"Indian J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0360","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1517\/17425247.2016.1151872","article-title":"Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery","volume":"13","author":"Rao","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0365","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/cmi.2017.104","article-title":"Gut-homing \u03b14\u03b27 CD4+ T cells: potential key players in both acute HIV infection and HIV-associated cancers","volume":"15","author":"Wang","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.002_bb0370","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.nano.2018.06.005","article-title":"Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells","volume":"14","author":"Cao","year":"2018","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.002_bb0375","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0380","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/mi.2008.35","article-title":"Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses","volume":"1","author":"Macal","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0385","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1007\/s11095-013-1107-3","article-title":"Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance","volume":"30","author":"Tan","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0390","doi-asserted-by":"crossref","first-page":"119264","DOI":"10.1016\/j.ijpharm.2020.119264","article-title":"Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids","volume":"582","author":"Schultz","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0395","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biomaterials.2018.10.012","article-title":"Chylomicron-pretended nano-bio self-assembling vehicle to promote lymphatic transport and GALTs target of oral drugs","volume":"188","author":"Mao","year":"2019","journal-title":"Biomaterials"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2023.10.002_bb0400","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0169-409X(98)00040-4","article-title":"Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract","volume":"34","author":"Ponchel","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0405","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mi.2013.30","article-title":"Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium","volume":"6","author":"Mabbott","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0410","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejpb.2017.07.013","article-title":"A comparison of three Peyer\u2019s patch \u201cM-like\u201d cell culture models: particle uptake, bacterial interaction, and epithelial histology","volume":"119","author":"Ahmad","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0415","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1208\/s12249-017-0876-0","article-title":"Darunavir-loaded lipid nanoparticles for targeting to HIV reservoirs","volume":"19","author":"Desai","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0420","doi-asserted-by":"crossref","first-page":"103090","DOI":"10.1016\/j.jddst.2021.103090","article-title":"Mechanistic evaluation of lymphatic targeting efficiency of Atazanavir sulfate loaded lipid nanocarriers: in-vitro and in-vivo studies","volume":"68","author":"Desai","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2214\/AJR.14.12908","article-title":"Clinicoradiologic evidence of pulmonary lymphatic spread in adult patients with tuberculosis","volume":"204","author":"Ko","year":"2015","journal-title":"Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0430","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ijpharm.2017.09.040","article-title":"Rifampicin lipid-polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer\u2019s patch uptake","volume":"532","author":"Bachhav","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.002_bb0435","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1021\/acs.molpharmaceut.8b00382","article-title":"Exploring Peyer\u2019s patch uptake as a strategy for targeted lung delivery of polymeric rifampicin nanoparticles","volume":"15","author":"Bachhav","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0440","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1208\/s12249-017-0876-0","article-title":"Darunavir-loaded lipid nanoparticles for targeting to HIV reservoirs","volume":"19","author":"Desai","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0445","series-title":"Journal of Investigative Dermatology Symposium Proceedings","article-title":"Structure, function, and molecular control of the skin lymphatic system","author":"Skobe","year":"2000"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20171868","article-title":"Organ-specific lymphatic vasculature: from development to pathophysiology","volume":"215","author":"Petrova","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0455","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2014.04.051","article-title":"Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers","volume":"193","author":"Ryan","year":"2014","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1690","article-title":"Recent advances in combination of microneedles and nanomedicines for lymphatic targeted drug delivery","volume":"13","author":"Permana","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0465","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2020.07.046","article-title":"Lymphatic targeting by albumin-hitchhiking: applications and optimisation","volume":"327","author":"Abdallah","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0475","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2022.11.034","article-title":"Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics","volume":"353","author":"Famta","year":"2023","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.002_bb0480","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.it.2006.10.005","article-title":"Targeting dendritic cells with biomaterials: developing the next generation of vaccines","volume":"27","author":"Reddy","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0485","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0490","first-page":"247","article-title":"Recent advances in lymphatic targeted drug delivery system for tumor metastasis","volume":"11","author":"Zhang","year":"2014","journal-title":"Cancer Biol. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.002_bb0495","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.002_bb0500","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/bip.20978","article-title":"Hyaluronic acid\u2013polyethyleneimine conjugate for target specific intracellular delivery of siRNA","volume":"89","author":"Jiang","year":"2008","journal-title":"Biopolymers: Orig. Res. Biomol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0505","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jss.2008.02.048","article-title":"Intralymphatic chemotherapy using a hyaluronan\u2013cisplatin conjugate","volume":"147","author":"Cai","year":"2008","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0510","doi-asserted-by":"crossref","first-page":"114325","DOI":"10.1016\/j.addr.2022.114325","article-title":"In vivo fate and intracellular trafficking of vaccine delivery systems","author":"Lee","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.002_bb0515","article-title":"Lasting impact of lipid nanoparticles","volume":"6","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0520","doi-asserted-by":"crossref","first-page":"1041025","DOI":"10.3389\/fimmu.2022.1041025","article-title":"The lymphatic system and COVID-19 vaccines","volume":"13","author":"Miyasaka","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0525","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.002_bb0530","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0535","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COH.0000000000000688","article-title":"Eliminating HIV reservoirs for a cure: the issue is in the tissue","volume":"16","author":"Busman-Sahay","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0540","first-page":"155","article-title":"Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques","volume":"42","author":"Kinman","year":"2006","journal-title":"JAIDS J. Acquir. Immune Deficiency . Syndr."},{"issue":"17","key":"10.1016\/j.jconrel.2023.10.002_bb0545","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000000421","article-title":"Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood","volume":"28","author":"Freeling","year":"2014","journal-title":"AIDS (London, England)"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"13","key":"10.1016\/j.jconrel.2023.10.002_bb0555","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1097\/01.aids.0000470770.30932.55","volume":"29","year":"2015","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0560","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS (London, England)"},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.002_bb0565","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.xphs.2018.03.005","article-title":"Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection","volume":"107","author":"McConnachie","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.002_bb0570","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0575","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2017.10.005","article-title":"Novel bilayer dissolving microneedle arrays with concentrated PLGA nano-microparticles for targeted intradermal delivery: proof of concept","volume":"265","author":"Vora","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0580","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","article-title":"Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension","volume":"292","author":"Mc Crudden","year":"2018","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0585","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.002_bb0590","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/pharmaceutics11070346","article-title":"Enhanced intradermal delivery of nanosuspensions of antifilariasis drugs using dissolving microneedles: a proof of concept study","volume":"11","author":"Permana","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0595","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2019.10.004","article-title":"Solid lipid nanoparticle-based dissolving microneedles: a promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis","volume":"316","author":"Permana","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0600","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.5530\/ijper.54.3s.148","article-title":"Effective single drug treatment of lymphatic filariasis through enhanced transdermal delivery of ivermectin liposomes using solid and dissolving microneedles","volume":"54","author":"Devineni","year":"2020","journal-title":"Indian J. Pharm. Educ. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0605","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0610","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.06.005","article-title":"Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: a humanized mouse model study","volume":"156","author":"Mandal","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0615","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","author":"Altice","year":"2019","journal-title":"Patient Prefer. Adherence"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0620","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00436-013-3696-5","article-title":"Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model","volume":"113","author":"Ali","year":"2014","journal-title":"Parasitol. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.002_bb0625","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1021\/acs.molpharmaceut.6b00206","article-title":"Subcutaneously administered ultrafine PLGA nanoparticles containing doxycycline hydrochloride target lymphatic filarial parasites","volume":"13","author":"Singh","year":"2016","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2006.04.017","article-title":"Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan\u2014a review","volume":"114","author":"George","year":"2006","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0635","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1080\/10717544.2022.2058646","article-title":"Application of chitosan\/alginate nanoparticle in oral drug delivery systems: prospects and challenges","volume":"29","author":"Li","year":"2022","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0640","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/app.32083","article-title":"Chitosan\/alginate nanoparticles stabilized by poloxamer for the controlled release of 5-fluorouracil","volume":"117","author":"Xing","year":"2010","journal-title":"J. Appl. Polym. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0645","first-page":"513","article-title":"Chitosan\u2013sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation","volume":"68","author":"Motwani","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.002_bb0650","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201800242","article-title":"Injectable biodegradable chitosan-alginate 3D porous gel scaffold for mRNA vaccine delivery","volume":"19","author":"Yan","year":"2019","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0655","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsanm.2c04714","article-title":"Chitosan\/alginate nanoparticles with sustained release of esculentoside A for burn wound healing","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.002_bb0660","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1007\/s00436-013-3466-4","article-title":"Improved antifilarial activity of ivermectin in chitosan\u2013alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi","volume":"112","author":"Ali","year":"2013","journal-title":"Parasitol. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.002_bb0665","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation","volume":"54","author":"Van\u2019t Klooster","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0670","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COH.0000000000000164","article-title":"Formulation and pharmacology of long-acting rilpivirine","volume":"10","author":"Williams","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.002_bb0675","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1152\/ajplegacy.1958.194.1.120","article-title":"Lymphatic permeability to albumin","volume":"194","author":"Patterson","year":"1958","journal-title":"Am. J. Physiol.-Legacy Content"},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.002_bb0680","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCRESAHA.116.309828","article-title":"Transcellular pathways in lymphatic endothelial cells regulate changes in solute transport by fluid stress","volume":"120","author":"Triacca","year":"2017","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.002_bb0685","first-page":"178","article-title":"Acyclovir","volume":"5","author":"Mehta","year":"2013","journal-title":"Pediatr. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0690","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2018.12.016","article-title":"Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs","volume":"294","author":"Frich","year":"2019","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.002_bb0695","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri3259","article-title":"The immunological life cycle of tuberculosis","volume":"12","author":"Ernst","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0700","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1473-3099(13)70253-6","article-title":"Is tuberculosis a lymphatic disease with a pulmonary portal?","volume":"14","author":"Behr","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0705","series-title":"Weekly Epidemiological Update on COVID-19 - 29 June 2023","author":"World Health Organisation","year":"2022"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0710","article-title":"The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes","author":"Feng","year":"2020","journal-title":"Preprint at medRxiv"},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.002_bb0715","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/v13071410","article-title":"Viral load and patterns of SARS-CoV-2 dissemination to the lungs, mediastinal lymph nodes, and spleen of patients with COVID-19 associated lymphopenia","volume":"13","author":"Abdullaev","year":"2021","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.002_bb0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-020-00647-z","article-title":"Unraveling the possible routes of SARS-COV-2 invasion into the central nervous system","volume":"22","author":"Lima","year":"2020","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jconrel.2023.10.002_bb0725","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbi.2020.04.080","article-title":"SARS-CoV2 entry and spread in the lymphatic drainage system of the brain","volume":"87","author":"Bostanc\u0131kl\u0131o\u011flu","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.002_bb0730","first-page":"97","article-title":"SARS-CoV-2\/COVID-19, lymphatic vessels, lymph, and lymphology","volume":"53","author":"Witte","year":"2020","journal-title":"Lymphology"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0735","series-title":"HIV","author":"World Health Organisation","year":"2022"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0740","series-title":"Lymphatic Filariasis","author":"World Health Organisation","year":"2022"},{"key":"10.1016\/j.jconrel.2023.10.002_bb0745","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2016.00012","article-title":"Animal models for HIV cure research","volume":"7","author":"Policicchio","year":"2016","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.002_bb0750","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrmicro2911","article-title":"Animal models for HIV\/AIDS research","volume":"10","author":"Hatziioannou","year":"2012","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:52:54Z","timestamp":1759164774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923006521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":150,"alternative-id":["S0168365923006521"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}